Study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
POLO Trial Shows Maintenance Olaparib Improves PFS in Metastatic Pancreatic Cancer - The ASCO Post
Treatment landscape of metastatic pancreatic cancer - Cancer Treatment Reviews
Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor
Efficacy – LYNPARZA® (olaparib)
Lynparza® for the Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Adenocarcinoma of the Pancreas
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Olaparib may delay metastatic pancreatic cancer in patients
FacingOurRisk on Twitter: "POLO: a study for pple w/pancreatic cancer & BRCA mutation olaparib (a PARP inhibitor) as maintenance therapy. https://t.co/ud1DOTbQJJ https://t.co/1s6t8fkFVH" / Twitter
Maintenance Olaparib vs Placebo in Germline BRCA-Mutated Metastatic Pancreatic Cancer - The ASCO Post
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications | Molecular Cancer | Full Text
ASCO GI 2021: Results From the Phase 3 POLO Trial
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink
Olaparib in Pancreas Cancer | Polo Trial | One oncologist breaks it down - YouTube
Cancer Trial Results
Phase III POLO Trial - Capsule Summary Slidesets - GI Cancers - 2019 ASCO Annual Meeting - Oncology - Clinical Care Options
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology
ASCO GI 2021: Results From the Phase 3 POLO Trial
5697_O REILLY Transcript.indd
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Efficacy – LYNPARZA® (olaparib)
Treatment Paradigm – LYNPARZA® (olaparib)
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
